|
MechanismMPXV A35R inhibitors |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
/ Not yet recruitingPhase 1/2IIT Phage-Antibiotic Combination Therapy for Multidrug-Resistant Infections: A Prospective Study
A multicenter, randomized, double-blind, placebo-controlled, phase II clinical study to evaluate the efficacy and safety of HL-21 tablets in adult patients with mild and moderate novel coronavirus infection (COVID-19).
Ultra-short treatment by advancing new regimens based on sitafloxacin and pyrazinamide for drug-susceptible pulmonary tuberculosis (UltraStar-SZ): A multi-arm, multi-stage, adaptive, multi-centre, randomised, controlled, open-label, non-inferiority trial
100 Clinical Results associated with Shenzhen Third People's Hospital
0 Patents (Medical) associated with Shenzhen Third People's Hospital
100 Deals associated with Shenzhen Third People's Hospital
100 Translational Medicine associated with Shenzhen Third People's Hospital